Autologous dendritic cell vaccine (Dana-Farber Cancer Institute)

This autologous dendritic cell (DC) therapy platform was developed at the Dana-Farber Cancer Institute for the treatment of advanced melanoma. The platform encompasses two primary vaccine strategies investigated in Phase II clinical trials (e.g., NCT00064740): one involving DCs pulsed with the gp100 melanoma-associated peptide, and another involving DCs fused with the patient's own inactivated tumor cells (DC-tumor fusion). The fusion approach creates a hybrid cell that combines the potent antigen-presenting and costimulatory capabilities of dendritic cells with the full antigenic repertoire of the autologous tumor, aiming to induce a broad, polyclonal T-cell response. These vaccines are designed to stimulate the patient's immune system to recognize and eliminate melanoma cells in patients with stage III or IV disease.

Other names

DC-tumor fusion vaccinegp100-pulsed dendritic cell vaccinegp-100-pulsed dendritic cell vaccinegp 100-pulsed dendritic cell vaccineautologous dendritic cell-tumor fusion vaccinetherapeutic autologous dendritic cells